{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:23:32Z","timestamp":1772749412851,"version":"3.50.1"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"The Sylvester Comprehensive Cancer Center","award":["5P30CA240139-04"],"award-info":[{"award-number":["5P30CA240139-04"]}]},{"name":"The Dowskin Family Foundation, and by National Institutes of Health","award":["2UM1-CA186644-06"],"award-info":[{"award-number":["2UM1-CA186644-06"]}]},{"name":"The Dowskin Family Foundation, and by National Institutes of Health","award":["1R37CA262510-01A1"],"award-info":[{"award-number":["1R37CA262510-01A1"]}]},{"name":"The Dowskin Family Foundation, and by National Institutes of Health","award":["1R21CA282543"],"award-info":[{"award-number":["1R21CA282543"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Society for Neuro-Oncology (SNO) marks its 30th anniversary in 2025, providing an opportunity to reflect on scientific advances and future directions in the field. Over 3 decades, SNO has catalyzed scientific innovation, education, mentorship, and global collaboration, advancing the care of patients with primary and metastatic brain tumors. Through its annual meeting and subspecialty conferences in pediatric neuro-oncology and brain metastases, as well as its journals, including Neuro-Oncology, Neuro-Oncology Practice, Neuro-Oncology Advances, and the recently launched Neuro-Oncology Pediatrics, SNO has established leading platforms for disseminating knowledge, sharing best practices, and shaping clinical, translational, and basic research worldwide. Scientific milestones during this period include the integration of molecular profiling into central nervous system tumor classification, advances in neuroimaging for diagnosis and treatment monitoring, targeted therapies for selected glioma patients, and the evolution of brain metastases management from whole-brain radiotherapy to multimodal strategies that incorporate targeted and immune-based therapies. Pediatric neuro-oncology has similarly advanced with the use of histomolecular diagnostics, refined risk stratification, and the development of novel targeted agents, alongside an increased emphasis on survivorship. Looking forward, emerging insights into the tumor microenvironment and novel immunotherapeutic approaches offer promising directions for future discovery and translation.<\/jats:p>","DOI":"10.1093\/neuonc\/noaf255","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:15:19Z","timestamp":1761830119000},"page":"7-18","source":"Crossref","is-referenced-by-count":0,"title":["Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-9329","authenticated-orcid":false,"given":"Macarena I","family":"de la Fuente","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Gampel","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"Nassiri","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane M","family":"Ida","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S","family":"Abdelbaki","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melike","family":"Pekmezci","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bagley","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob S","family":"Young","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-5396","authenticated-orcid":false,"given":"Rimas V","family":"Lukas","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-0757","authenticated-orcid":false,"given":"Javier","family":"Villanueva-Meyer","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1839-5421","authenticated-orcid":false,"given":"Anna","family":"Lasorella","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4885","authenticated-orcid":false,"given":"Jann N","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-5045","authenticated-orcid":false,"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-4800","authenticated-orcid":false,"given":"Daphne","family":"Haas-Kogan","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami , Miami (M.I.D., B.G.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-786X","authenticated-orcid":false,"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana Farber Cancer Institute , Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-364X","authenticated-orcid":false,"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurosurgery, University of California , San Francisco (S.M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026030516320857900_noaf255-B1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the Central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026030516320857900_noaf255-B2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"2026030516320857900_noaf255-B4","first-page":"vdae228","article-title":"cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics","volume":"7","author":"Aldape","year":"2025","journal-title":"Neurooncol Adv"},{"key":"2026030516320857900_noaf255-B5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Cancer Genome Atlas Research Network: McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"2026030516320857900_noaf255-B6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"2026030516320857900_noaf255-B7","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2026030516320857900_noaf255-B8","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B9","first-page":"1175","article-title":"Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p","volume":"145","author":"Reifenberger","year":"1994","journal-title":"Am J Pathol"},{"key":"2026030516320857900_noaf255-B10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"key":"2026030516320857900_noaf255-B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11060-012-1040-z","article-title":"H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?","volume":"112","author":"Gessi","year":"2013","journal-title":"J Neurooncol"},{"key":"2026030516320857900_noaf255-B12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"2026030516320857900_noaf255-B13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"2026030516320857900_noaf255-B14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00401-017-1710-1","article-title":"H3-\/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers","volume":"134","author":"Korshunov","year":"2017","journal-title":"Acta Neuropathol"},{"key":"2026030516320857900_noaf255-B15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00401-018-1883-2","article-title":"Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile","volume":"136","author":"Solomon","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026030516320857900_noaf255-B16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-018-1820-4","article-title":"Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway","volume":"135","author":"Pekmezci","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026030516320857900_noaf255-B17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","article-title":"New brain tumor entities emerge from molecular classification of CNS-PNETs","volume":"164","author":"Sturm","year":"2016","journal-title":"Cell"},{"key":"2026030516320857900_noaf255-B18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"2026030516320857900_noaf255-B19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","article-title":"Medulloblastoma comprises four distinct molecular variants","volume":"29","author":"Northcott","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","article-title":"Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of\u00a0group 3 and group 4 subtypes","volume":"138","author":"Sharma","year":"2019","journal-title":"Acta Neuropathol"},{"key":"2026030516320857900_noaf255-B21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/neuonc\/noz235","article-title":"Molecular subgrouping of atypical teratoid\/rhabdoid tumors-a reinvestigation and current consensus","volume":"22","author":"Ho","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1148\/radiology.174.2.2153310","article-title":"Gliomas: classification with MR imaging","volume":"174","author":"Dean","year":"1990","journal-title":"Radiology"},{"key":"2026030516320857900_noaf255-B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004728-199001000-00002","article-title":"Clinical experience with routine Gd-DTPA administration for MR imaging of the brain","volume":"14","author":"Schwaighofer","year":"1990","journal-title":"J Comput Assist Tomogr"},{"key":"2026030516320857900_noaf255-B24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/radiology.191.1.8134596","article-title":"Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings","volume":"191","author":"Aronen","year":"1994","journal-title":"Radiology"},{"key":"2026030516320857900_noaf255-B25","first-page":"925","article-title":"Diffusion-weighted MR imaging of the brain: value of differentiating between extraaxial cysts and epidermoid tumors","volume":"11","author":"Tsuruda","year":"1990","journal-title":"AJNR Am J Neuroradiol"},{"key":"2026030516320857900_noaf255-B26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/nbm.1544","article-title":"Diffusion imaging of brain tumors","volume":"23","author":"Maier","year":"2010","journal-title":"NMR Biomed"},{"key":"2026030516320857900_noaf255-B27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1227\/00006123-199609000-00015","article-title":"Functional magnetic resonance imaging mapping of the motor cortex in patients with cerebral tumors","volume":"39","author":"Mueller","year":"1996","journal-title":"Neurosurgery"},{"key":"2026030516320857900_noaf255-B28","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/0008-5472.CAN-18-0221","article-title":"Metabolic imaging of the human brain with hyperpolarized (13)C pyruvate demonstrates (13)C lactate production in brain tumor patients","volume":"78","author":"Miloushev","year":"2018","journal-title":"Cancer Res"},{"key":"2026030516320857900_noaf255-B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1148\/radiol.2019182391","article-title":"Hyperpolarized (13)C MRI: state of the art and future directions","volume":"291","author":"Wang","year":"2019","journal-title":"Radiology"},{"key":"2026030516320857900_noaf255-B30","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S1470-2045(25)00193-7","article-title":"Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas","volume":"26","author":"Galldiks","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cpet.2021.03.005","article-title":"Theranostics in brain tumors","volume":"16","author":"Shooli","year":"2021","journal-title":"PET Clin"},{"key":"2026030516320857900_noaf255-B32","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B33","doi-asserted-by":"crossref","first-page":"1267615","DOI":"10.3389\/fradi.2023.1267615","article-title":"Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration","volume":"3","author":"Sanvito","year":"2023","journal-title":"Front Radiol"},{"key":"2026030516320857900_noaf255-B34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary Central nervous system lymphoma: guideline statement from the international primary CNS lymphoma collaborative group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/neuonc\/noaa141","article-title":"Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas","volume":"22","author":"Boxerman","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B37","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/neuonc\/noad189","article-title":"RANO 2.0: update to the response assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B39","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3174\/ajnr.A8396","article-title":"A neuroradiologist\u2019s guide to operationalizing the Response Assessment in Neuro-Oncology (RANO) criteria version 2.0 for gliomas in adults","volume":"45","author":"Ellingson","year":"2024","journal-title":"AJNR Am J Neuroradiol"},{"key":"2026030516320857900_noaf255-B40","doi-asserted-by":"crossref","first-page":"105273","DOI":"10.1016\/j.compbiomed.2022.105273","article-title":"An artificial intelligence framework and its bias for brain tumor segmentation: a narrative review","volume":"143","author":"Das","year":"2022","journal-title":"Comput Biol Med"},{"key":"2026030516320857900_noaf255-B41","doi-asserted-by":"crossref","first-page":"106405","DOI":"10.1016\/j.compbiomed.2022.106405","article-title":"Brain tumor segmentation of MRI images: a comprehensive review on the application of artificial intelligence tools","volume":"152","author":"Ranjbarzadeh","year":"2023","journal-title":"Comput Biol Med"},{"key":"2026030516320857900_noaf255-B42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41698-024-00575-0","article-title":"Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment","volume":"8","author":"Khalighi","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026030516320857900_noaf255-B43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B44","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B47","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B50","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B54","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (dordaviprone) in recurrent H3 K27M-Mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B56","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B57","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with Von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study","volume":"25","author":"Iliopoulos","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"2026030516320857900_noaf255-B59","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"2026030516320857900_noaf255-B60","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/bpa.12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff","year":"2022","journal-title":"Brain Pathol"},{"key":"2026030516320857900_noaf255-B61","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B62","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B63","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/neuonc\/noae242","article-title":"Development and validation of a molecular classifier of meningiomas","volume":"27","author":"Landry","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"2026030516320857900_noaf255-B65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B67","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","article-title":"Advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B68","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","article-title":"Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"key":"2026030516320857900_noaf255-B69","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1038\/s41598-020-70514-z","article-title":"Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression","volume":"10","author":"Karimi","year":"2020","journal-title":"Sci Rep"},{"key":"2026030516320857900_noaf255-B70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"key":"2026030516320857900_noaf255-B71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B73","doi-asserted-by":"crossref","first-page":"Jco2018783118","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-Mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026030516320857900_noaf255-B74","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030516320857900_noaf255-B75","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B77","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B80","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"2026030516320857900_noaf255-B81","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","article-title":"Subtype switching in breast cancer brain metastases: a multicenter analysis","volume":"22","author":"Hulsbergen","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B82","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/neuonc\/noab120","article-title":"The 2021 WHO classification of tumors of the central nervous system: clinical implications","volume":"23","author":"Wen","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B83","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/neuonc\/noab143","article-title":"DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology","volume":"23","author":"Pratt","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B84","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/neuonc\/noy070","article-title":"Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma","volume":"20","author":"Gupta","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B85","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/neuonc\/noac073","article-title":"Enhancing GD2 CAR T-cell therapy with IGF-1R blockade: are DIPG CAR T cells ready for combinatorial therapy?","volume":"24","author":"Franson","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B86","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/neuonc\/noac035","article-title":"Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients","volume":"24","author":"Miller","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B87","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(20)30166-2","article-title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the response assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Cooney","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026030516320857900_noaf255-B88","first-page":"vdac182","article-title":"Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment","volume":"5","author":"Tsai","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026030516320857900_noaf255-B89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/neuonc\/nox087","article-title":"Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the response assessment in pediatric Neuro-Oncology committee","volume":"20","author":"Warren","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/neuonc\/noad195","article-title":"Pediatric low-grade glioma: state-of-the-art and ongoing challenges","volume":"26","author":"Fangusaro","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B91","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/noae259","article-title":"The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma","volume":"27","author":"de la Fuente","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B92","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B93","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/neuonc\/noae008","article-title":"A paradigm shift in how we treat pediatric low-grade glioma-Targeting the molecular drivers","volume":"26","author":"Ziegler","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B94","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/neuonc\/noy116","article-title":"Proton therapy patterns of care among pediatric and adult patients with CNS tumors","volume":"20","author":"Tseng","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B95","first-page":"3","article-title":"Survivorship care planning in neuro-oncology","volume":"5","author":"Leeper","year":"2018","journal-title":"Neurooncol Pract"},{"key":"2026030516320857900_noaf255-B96","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B98","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026030516320857900_noaf255-B99","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B101","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"2026030516320857900_noaf255-B102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat Commun"},{"key":"2026030516320857900_noaf255-B103","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"2026030516320857900_noaf255-B104","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2022.40.16_suppl.2004","article-title":"Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma","volume":"40","author":"Reardon","year":"2022","journal-title":"JCO"},{"key":"2026030516320857900_noaf255-B105","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B106","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"2026030516320857900_noaf255-B107","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B108","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1158\/1538-7445.AM2025-3527","article-title":"Abstract 3527: low-intensity pulsed focused ultrasound, with microbubbles and immune adjuvants, promotes CNS epitope spreading, improving CAR T cell therapy for heterogeneous brain tumors","volume":"85","author":"Gallus","year":"2025","journal-title":"Cancer Res"},{"key":"2026030516320857900_noaf255-B109","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-20-3760","article-title":"Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to \u00adimmunotherapy in preclinical glioma models","volume":"27","author":"Sabbagh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026030516320857900_noaf255-B110","doi-asserted-by":"crossref","first-page":"114018","DOI":"10.1016\/j.jconrel.2025.114018","article-title":"Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma","volume":"385","author":"Shumer-Elbaz","year":"2025","journal-title":"J Control Release"},{"key":"2026030516320857900_noaf255-B111","doi-asserted-by":"crossref","first-page":"122913","DOI":"10.1016\/j.biomaterials.2024.122913","article-title":"Targeted sonodynamic therapy induces tumor cell quasi-immunogenic ferroptosis and macrophage immunostimulatory autophagy in glioblastoma","volume":"315","author":"Wang","year":"2025","journal-title":"Biomaterials"},{"key":"2026030516320857900_noaf255-B112","doi-asserted-by":"crossref","first-page":"109772","DOI":"10.1016\/j.clim.2023.109772","article-title":"Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma","volume":"256","author":"Zhou","year":"2023","journal-title":"Clin Immunol"},{"key":"2026030516320857900_noaf255-B113","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","article-title":"Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas","volume":"15","author":"Arrieta","year":"2024","journal-title":"Nat Commun"},{"key":"2026030516320857900_noaf255-B114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40478-021-01156-z","article-title":"Macrophages and microglia: the cerberus of glioblastoma","volume":"9","author":"Buonfiglioli","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2026030516320857900_noaf255-B115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/neuonc\/noac055","article-title":"T lymphocytes as dynamic regulators of glioma pathobiology","volume":"24","author":"Cordell","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B116","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","article-title":"Complex neural-immune interactions shape glioma immunotherapy","volume":"58","author":"Song","year":"2025","journal-title":"Immunity"},{"key":"2026030516320857900_noaf255-B117","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.devcel.2022.12.011","article-title":"Neurons as stromal drivers of nervous system cancer formation and progression","volume":"58","author":"Anastasaki","year":"2023","journal-title":"Dev Cell"},{"key":"2026030516320857900_noaf255-B118","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"key":"2026030516320857900_noaf255-B119","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.immuni.2024.09.007","article-title":"Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations","volume":"57","author":"Ross","year":"2024","journal-title":"Immunity"},{"key":"2026030516320857900_noaf255-B120","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177413","article-title":"Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma","volume":"134","author":"Tripathi","year":"2024","journal-title":"J Clin Invest"},{"key":"2026030516320857900_noaf255-B121","doi-asserted-by":"crossref","first-page":"e2427073122","DOI":"10.1073\/pnas.2427073122","article-title":"A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026030516320857900_noaf255-B122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026030516320857900_noaf255-B123","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163802","article-title":"A paracrine circuit of IL-1\u03b2\/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression","volume":"133","author":"Chen","year":"2023","journal-title":"J Clin Invest"},{"key":"2026030516320857900_noaf255-B124","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B125","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ccell.2024.08.012","article-title":"Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence","volume":"42","author":"Watson","year":"2024","journal-title":"Cancer Cell"},{"key":"2026030516320857900_noaf255-B126","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1158\/2159-8290.CD-22-0455","article-title":"Targeting microglial metabolic rewiring synergizes with Immune-Checkpoint blockade therapy for glioblastoma","volume":"13","author":"Ye","year":"2023","journal-title":"\u00adCancer Discov"},{"key":"2026030516320857900_noaf255-B127","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.1038\/s41467-024-54569-4","article-title":"Human single cell RNA-sequencing reveals a targetable CD8(+) exhausted T cell population that maintains mouse low-grade glioma growth","volume":"15","author":"Barakat","year":"2024","journal-title":"Nat Commun"},{"key":"2026030516320857900_noaf255-B128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-Cell mapping of human brain cancer reveals Tumor-Specific instruction of Tissue-Invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"key":"2026030516320857900_noaf255-B129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat Med"},{"key":"2026030516320857900_noaf255-B130","first-page":"vdab194","article-title":"Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation","volume":"4","author":"de Andrade Costa","year":"2022","journal-title":"\u00adNeurooncol Adv"},{"key":"2026030516320857900_noaf255-B131","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-18-2564","article-title":"Immune checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8(+) T cells is determined by their differentiation status in glioblastoma","volume":"25","author":"Park","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026030516320857900_noaf255-B132","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/neuonc\/noae054","article-title":"NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma","volume":"26","author":"Anastasaki","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026030516320857900_noaf255-B133","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1038\/s41467-022-30466-6","article-title":"Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1","volume":"13","author":"Anastasaki","year":"2022","journal-title":"Nat Commun"},{"key":"2026030516320857900_noaf255-B134","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","article-title":"NF1 mutation drives neuronal activity-dependent initiation of optic glioma","volume":"594","author":"Pan","year":"2021","journal-title":"Nature"},{"key":"2026030516320857900_noaf255-B135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"2026030516320857900_noaf255-B136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/2159-8290.CD-24-0194","article-title":"Cancer neuroscience of brain tumors: from multicellular networks to Neuroscience-Instructed cancer therapies","volume":"15","author":"Venkataramani","year":"2025","journal-title":"Cancer Discov"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf255\/65175636\/noaf255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/1\/7\/65175636\/noaf255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/1\/7\/65175636\/noaf255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:32:28Z","timestamp":1772746348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/1\/7\/8314223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf255","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,4]]}}}